PT-141 (Bremelanotide) Pregnancy & Lactation Safety: What the Evidence Actually Shows

HealthRX.com

The Vyleesi label advises against use during pregnancy

Print or save as PDF

Key numbers

  • 16 timesFetal harm in pregnant dogs at exposure at least 16 times human exposure (AUC basis)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 3 to 8 timesPost-implantation loss in pregnant dogs compared with controls, across all treated dosesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 2.7 hoursMean terminal half-life after a 1.75 mg subcutaneous dose of bremelanotideSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 125 timesDevelopmental delays in mouse pups at 30 mg/kg/day and above, versus human AUCSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

FDA label facts for bremelanotide

The FDA label read for bremelanotide (Vyleesi, application NDA210557) was last revised on 2026-11-05. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.

FDA label facts for bremelanotide: the figures
MeasureValueNote
Label revision date2026-11-05
Label readVyleesiNDA210557, brand-name application
Boxed warningNo
Pregnancy sectionPresent
Lactation sectionPresent
Pediatric use sectionPresent
Geriatric use sectionPresent

Source: FDA drug label via openFDA, viewable on NIH DailyMed, data as of Nov 11, 2026

How this was calculated

Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.

Scope: One label: the newest prescription label for single-ingredient bremelanotide from an original manufacturer

Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.

Download the data (CSV)

At a glance

  • Label position on pregnancy / Use not recommended; stop if pregnancy is suspected [1]
  • Contraindications / Uncontrolled hypertension or known cardiovascular disease [1]
  • Contraception / Effective contraception advised while taking Vyleesi [1]
  • Human pregnancy data / Too few pregnancies in trials to judge risk [1]
  • Animal findings / Fetal harm in dogs at 16 times human exposure or more; developmental delays in mouse offspring at 125 times [1]
  • Breastfeeding / No human milk data [1]
  • Half-life / About 2.7 hours (range 1.9 to 4.0) [1]
  • Approved population / Premenopausal women with acquired, generalized HSDD only [1]

What does the Vyleesi label say about pregnancy?

The pregnancy section of the Vyleesi prescribing information says that use of Vyleesi in pregnant women may be associated with the potential for fetal harm based on animal findings, that women of reproductive potential should use effective contraception while taking it, and that the drug should be discontinued if pregnancy is suspected [1]. The contraception instruction is repeated in Section 8.3, which covers females and males of reproductive potential [1].

Pregnancy is not a contraindication on this label. The contraindications section lists two conditions: uncontrolled hypertension and known cardiovascular disease [1].

FDA approved a labeling supplement (S-005) on October 22, 2026 that revises Section 8 (Use in Specific Populations) and the patient information [2]. The label wording described on this page is from the DailyMed label effective November 13, 2025 [1].

What did the animal studies show?

The label describes reproductive and developmental studies in two species, dogs and mice.

Pregnant dogs, 8 per dose group, received subcutaneous bremelanotide at 2, 8 or 20 mg/kg/day from gestation day 18 to 35, the period the label describes as implantation through late embryogenesis in the dog [1]. Post-implantation loss was about 3 to 8 times higher than in controls across all three treated groups and was not dose-dependent, so a developmental no-observed-effect level was not set [1]. At the low dose of 2 mg/kg/day, exposure was about 16 times the human exposure based on AUC [1]. The label's risk summary states that fetal harm occurred at exposures greater than or equal to 16 times the maximum recommended dose [1].

Female mice, 30 per group, were dosed from gestation day 6 through lactation day 28 at 0, 30, 75 or 150 mg/kg/day, and two generations of offspring were assessed [1]. There were no effects on reproductive parameters in the parent or first-generation animals at doses up to 150 mg/kg/day, about 760 times the human AUC [1]. Developmental delays appeared in the first-generation pups at 30 mg/kg/day and above, about 125 times the human AUC, so a developmental no-observed-effect level was not set [1]. There were no significant effects on growth and development of the second-generation pups [1].

The label states that the lowest bremelanotide dose associated with fetal harm has not been identified in either species, and gives that as its reason for advising effective contraception [1].

What human pregnancy data exist?

The label states that the few pregnancies that occurred in women exposed to Vyleesi during clinical trials are insufficient to determine whether there is a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes [1].

In the two RECONNECT trials, all patients in heterosexual relationships were required to use an effective form of contraception [1].

What happens if pregnancy is suspected or confirmed?

If pregnancy is suspected, the Vyleesi label advises discontinuing the drug. It also encourages women exposed during pregnancy to call the Vyleesi Pregnancy Exposure Registry at (800) 922-1038 [1].

Questions worth asking

Choose the questions you want to keep

How long does bremelanotide stay in the body?

The mean terminal half-life after a 1.75 mg subcutaneous dose is about 2.7 hours, with a range of 1.9 to 4.0 hours [1]. The label's instructions are to use effective contraception while taking Vyleesi and to discontinue the drug if pregnancy is suspected [1].

What is known about breastfeeding?

Section 8.2 of the label states that there is no information on the presence of bremelanotide or its metabolites in human milk, on the effects on the breastfed infant, or on the effects on milk production [1]. The label says the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Vyleesi and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition [1].

The animal offspring findings come from the mouse pre- and postnatal study, in which mothers were dosed through lactation day 28; developmental delays appeared in first-generation pups at exposures about 125 times the human AUC or higher [1]. That study did not measure drug in human milk or in a nursing infant [1].

Does this apply to compounded PT-141?

Vyleesi is the FDA-approved bremelanotide product: a 1.75 mg subcutaneous autoinjector, NDA 210557, approved June 21, 2019 [1][3]. PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug [1][4]. The pregnancy and lactation information here comes from the Vyleesi label. Compounded PT-141 does not have FDA-approved labeling, and FDA does not verify the safety, effectiveness or quality of compounded drugs before marketing [1][5].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. Which two conditions does the Vyleesi label list as contraindications?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

Is PT-141 safe to use during pregnancy?
The Vyleesi label does not recommend use in pregnancy and advises women of reproductive potential to use effective contraception while taking it, discontinuing the drug if pregnancy is suspected [1]. Fetal harm occurred in pregnant dogs at exposures at least 16 times the human exposure, and the lowest dose causing fetal harm has not been identified in either animal species tested [1].
I took PT-141 before I knew I was pregnant. What is known?
Very little. The label states that the few pregnancies in women exposed to Vyleesi during clinical trials are insufficient to determine whether there is a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes [1]. The label encourages exposed women and their healthcare providers to call the Vyleesi Pregnancy Exposure Registry at (800) 922-1038 [1].
Can I use bremelanotide while breastfeeding?
The label has no information on bremelanotide in human milk, effects on the breastfed infant, or effects on milk production, and says the benefits of breastfeeding should be weighed against the mother's clinical need for Vyleesi and any potential adverse effects on the child [1].
Does bremelanotide affect fertility?
In the mouse study, the label reports no effects on reproductive parameters in the parent or first-generation animals at doses up to 150 mg/kg/day, about 760 times the human AUC [1]. The label's section on females and males of reproductive potential addresses contraception and stopping the drug if pregnancy is suspected [1].
How long before trying to conceive should bremelanotide be stopped?
The label's instructions are to use effective contraception while taking Vyleesi and to discontinue the drug if pregnancy is suspected [1]. The mean terminal half-life is about 2.7 hours, range 1.9 to 4.0 hours [1].
Is compounded PT-141 covered by the same pregnancy warnings as Vyleesi?
The pregnancy and lactation statements come from the FDA-approved Vyleesi label, NDA 210557 [1][3]. Compounded or research-use PT-141 is not Vyleesi, is not an FDA-approved drug, and does not carry FDA-approved labeling; FDA does not verify the safety, effectiveness or quality of compounded drugs before marketing [1][4][5].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is bremelanotide an injection?

Yes. Vyleesi is a 1.75 mg subcutaneous autoinjector, so it is given under the skin. Its mean terminal half-life after that dose is about 2.7 hours, with a range of 1.9 to 4.0 hours.

Are Vyleesi and PT-141 the same?

No. Vyleesi is the FDA-approved bremelanotide product, a 1.75 mg subcutaneous autoinjector approved June 21, 2019 under NDA 210557. PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug, and FDA does not verify its safety, effectiveness or quality before marketing.

Who should not take bremelanotide?

The Vyleesi label lists two contraindications: uncontrolled hypertension and known cardiovascular disease. Pregnancy is not a contraindication on that label. Instead, it advises effective contraception while taking the drug and stopping it if pregnancy is suspected.

References

Show all 5 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Official web page.
  5. Compounding and the FDA: Questions and Answers | FDA.
Evidence overview for PT-141 (Bremelanotide) Pregnancy & Lactation Safety: What the Evidence Actually Shows